Lane WS, Favaro E, Rathor N, et al. - In adults with type 2 diabetes (T2D) not optimally controlled with a basal-bolus regimen, researchers conducted this multicenter, double-blind, treat-to-target trial to test the safety and effectiveness of fast-acting insulin aspart (faster aspart) vs insulin aspart (IAsp), both with insulin degludec with or without metformin. This trial randomized candidates to faster aspart (n = 546) or IAsp (n = 545). Faster aspart, in conjunction with insulin degludec, provided better overall glycemic control, superior postprandial glucose control, and a lower incidence of severe or BG-confirmed hypoglycemia vs IAsp in adults with T2D not optimally controlled with a basal-bolus regimen.